The Swiss and Indian pharmaceutical industries play important roles in the global healthcare market, but their strengths and business models differ. Switzerland is known for research-driven pharmaceutical companies and innovative medicines, while India has established itself as a major manufacturer and exporter of affordable generic drugs.

AdvertisementThe Puranic

Switzerland is home to major pharmaceutical companies such as Roche and Novartis, which have significant research and development operations. The country also has Sandoz, a leading manufacturer of generic medicines and biosimilars. These products provide alternatives to certain established medicines and biological treatments, helping broaden access to healthcare.

India, meanwhile, has become an important supplier of generic medicines to international markets. Companies such as Sun Pharmaceutical Industries, Dr. Reddy's Laboratories and Cipla manufacture a wide range of medicines for domestic and overseas patients. India's large manufacturing base and competitive production costs help support its role in the global pharmaceutical supply chain.

However, the two industries are not completely different. Swiss companies also manufacture generics, while Indian pharmaceutical businesses are investing in research, complex medicines and biosimilars. Both face challenges involving regulatory requirements, competition, manufacturing costs and access to international markets.

Recent developments at Sandoz highlight some of the pressures facing the global pharmaceutical industry. On October 28, 2026, the company lowered its 2026 sales growth forecast after supply constraints affected its third-quarter results, although it raised its expected core earnings margin.

The announcement does not establish a direct impact on Indian drugmakers. However, it highlights broader issues such as supply reliability, market competition and the challenges pharmaceutical companies face while trying to maintain growth.

As global demand for affordable and advanced treatments continues, both Switzerland and India are likely to remain important participants in the pharmaceutical sector, with different strengths contributing to the wider healthcare market.